Nykredit A S Makes New Investment in Tenet Healthcare Corporation $THC

Nykredit A S bought a new stake in Tenet Healthcare Corporation (NYSE:THC) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,208 shares of the company’s stock, valued at approximately $600,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hsbc Holdings PLC increased its stake in shares of Tenet Healthcare by 3,478.7% in the 4th quarter. Hsbc Holdings PLC now owns 266,400 shares of the company’s stock worth $53,269,000 after acquiring an additional 258,956 shares in the last quarter. Jackson Creek Investment Advisors LLC grew its holdings in Tenet Healthcare by 235.6% in the fourth quarter. Jackson Creek Investment Advisors LLC now owns 9,032 shares of the company’s stock worth $1,795,000 after purchasing an additional 6,341 shares during the period. Brandywine Global Investment Management LLC increased its stake in shares of Tenet Healthcare by 20.5% during the fourth quarter. Brandywine Global Investment Management LLC now owns 126,248 shares of the company’s stock valued at $25,088,000 after purchasing an additional 21,435 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in shares of Tenet Healthcare during the first quarter valued at approximately $4,812,000. Finally, Cerity Partners LLC boosted its position in shares of Tenet Healthcare by 8.4% in the 4th quarter. Cerity Partners LLC now owns 156,141 shares of the company’s stock worth $31,028,000 after purchasing an additional 12,060 shares in the last quarter. 95.44% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Tenet Healthcare

In other news, Director Cecil D. Haney sold 1,300 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $278.03, for a total transaction of $361,439.00. Following the completion of the sale, the director owned 12,553 shares of the company’s stock, valued at $3,490,110.59. This represents a 9.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Tammy Romo sold 2,500 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $260.83, for a total transaction of $652,075.00. Following the completion of the transaction, the director owned 28,284 shares in the company, valued at $7,377,315.72. This trade represents a 8.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 109,189 shares of company stock valued at $29,264,109 in the last 90 days. 0.97% of the stock is owned by company insiders.

Tenet Healthcare Stock Up 0.1%

THC opened at $265.28 on Tuesday. The stock has a market capitalization of $21.36 billion, a price-to-earnings ratio of 10.23, a PEG ratio of 1.01 and a beta of 1.23. The firm has a 50 day moving average price of $239.64 and a 200-day moving average price of $211.31. Tenet Healthcare Corporation has a twelve month low of $157.58 and a twelve month high of $283.05. The company has a quick ratio of 1.35, a current ratio of 1.41 and a debt-to-equity ratio of 2.00.

Tenet Healthcare (NYSE:THC) last posted its earnings results on Thursday, July 23rd. The company reported $6.12 EPS for the quarter, topping analysts’ consensus estimates of $4.26 by $1.86. The business had revenue of $6.04 billion during the quarter, compared to the consensus estimate of $5.43 billion. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The firm’s revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.02 EPS. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. Equities research analysts forecast that Tenet Healthcare Corporation will post 21.04 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on THC. Robert W. Baird lifted their price objective on Tenet Healthcare from $210.00 to $280.00 and gave the company a “neutral” rating in a research note on Tuesday, July 28th. Royal Bank Of Canada increased their target price on Tenet Healthcare from $236.00 to $283.00 and gave the stock an “outperform” rating in a research note on Monday, July 27th. Stephens reaffirmed an “overweight” rating and issued a $285.00 price target on shares of Tenet Healthcare in a research report on Monday, July 27th. Truist Financial upped their price target on shares of Tenet Healthcare from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $305.00 price objective on shares of Tenet Healthcare in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Tenet Healthcare currently has an average rating of “Buy” and a consensus price target of $273.00.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.